Hansoh Pharma’s Breakthrough in Cancer Drug Development

Hansoh Pharmaceutical Group Company Limited (HK:3692) has released an update.

Hansoh Pharmaceutical Group Company Limited has announced that its B7-H3-targeted antibody-drug conjugate, HS-20093, has been granted Breakthrough Therapy Designation by China’s National Medical Products Administration for treating small cell lung cancer. This promising development follows a licensing agreement with GlaxoSmithKline, which is conducting global trials of the drug. Such advancements could significantly impact Hansoh’s market position and attract investor interest.

For further insights into HK:3692 stock, check out TipRanks’ Stock Analysis page.